Optimisation of T2*-weighted MRI for the detection of small veins in multiple sclerosis at 3T and 7T
Nikos Evangelou - Consultant Neurologist in Nottinghamshire | Circle Health Group
Nikos EVANGELOU | Professor (Associate) | Doctor of Philosophy | University of Nottingham, Nottingham | Notts | Division of Neurosciences and mental health
The only way to manage neurodegeneration in MS is to prevent it with effective anti-inflammatory therapy: Yes
Experts - The University of Nottingham
MattBrookesBrigadiervisit - The News Room
Doctors warn of rise in nerve damage linked to nitrous oxide | Nitrous oxide (laughing gas) | The Guardian
Nottingham researchers awarded by MS Society to support DELIVER MS trial - The University of Nottingham
Nikos Evangelou - The University of Nottingham
Sign up to the UK MS Register today | Our friends over at the UK MS Register are researching the link between COVID-19 and multiple sclerosis - can you help? The more
PDF) Impact of mass vaccination on SARS-CoV-2 infections among the total multiple sclerosis population receiving immunomodulatory disease-modifying therapies in England
PDF) Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS): Study protocol for a randomised controlled trial
Nikos EVANGELOU | Professor (Associate) | Doctor of Philosophy | University of Nottingham, Nottingham | Notts | Division of Neurosciences and mental health
The MRI central vein marker; differentiating PPMS from RRMS and ischemic SVD
Dr Nikos Evangelou | Neurology Academy
How does cold weather affect Multiple Sclerosis? - YouTube
Stream episode Enabling UK-wide participation in MS real-world evidence: COVID-19 & beyond by Biogen Neurology Talks podcast | Listen online for free on SoundCloud
Mental health of people with multiple sclerosis during the COVID-19 outbreak: A prospective cohort and cross-sectional case–co
Dr Daniel Ontaneda Outlines 2 Approaches to Treating MS and the Trial to Identify the Best One
Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying
SARS-CoV-2, COVID-19, and managing MS: What have… | Neurology Academy
Is early intensive treatment best? | MS Society
SARS-CoV-2, COVID-19, and managing MS: What have… | Neurology Academy
1200+ "Evangelou" profiles | LinkedIn
Heat sensitivity and MS | MS Trust
